India's parliamentary committee criticized the drug pricing regulator for approving a 50% price increase on 11 drug formulations in October. This move affects the poorest citizens. The National Pharmaceutical Pricing Authority made the decision to accommodate rising production costs and ensure drug availability, but the committee demands a detailed explanation for its impact on the poorest.
